… Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, 2018 … the two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis …
… R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program … the unmet need in DEB and the current treatment landscape. Axiomer®: ProQR will introduce its novel, proprietary RNA …
… ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB LEIDEN, … 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA editing technology during the TIDES: …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR … (Nasdaq:PRQR), today announced that a presentation titled “Axiomer ® Technology: Therapeutic Oligonucleotides for …
… Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter … in advancing the company’s novel and proprietary Axiomer ® RNA editing technology. The board now consists of …
… focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer, closer to the clinic. Today we are delighted to … announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
… immense, says Bart Klein, who was at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about the promise of Axiomer® technology: “This opens up a whole new way of …
The presentation reviews EONs structure activity, the potential of the Axiomer platform as well as its applicability for the treatment of liver originated disorders. Presented at TIDES USA on May 9, 2023 by Gerard Platenburg - ProQR Therapeutics.
